# A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Study · id `cardio:ct-nct04557462` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04557462](<https://clinicaltrials.gov/study/NCT04557462>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04557462

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 540 participants.

## Technical summary

Registry record NCT04557462. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-20 (actual); primary completion 2030-12-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 540 participants (planned count; ClinicalTrials.gov record NCT04557462, source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)
- Started: 2021-09-20 (actual) (ClinicalTrials.gov record NCT04557462, source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)
- Primary completion: 2030-12-04 (anticipated) (ClinicalTrials.gov record NCT04557462, source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)
- Completion: 2030-12-04 (anticipated) (ClinicalTrials.gov record NCT04557462, source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Hong Kong SAR China; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Norway; Russia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT04557462, source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04557462-2026-10-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Condition: Primary IgA Nephropathy
- Intervention (Drug): LNP023
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: d58bd92a913c3d4e5645fbc8e3c560a72383465ab92b564086127343320bccd0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
